secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001558370-24-006543
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure posts Q1 net loss of $17.1M; cash $96M; NC410 data at ASCO June 1
--------------------------------------------------------------------------

- Cash $96.0M as of March 31, 2024, down $12.3M from Q4 2023; expected to fund operations into H2 2026.
- Net loss of $17.1M for Q1 2024 vs $16.1M in Q1 2023; R&D $11.4M, G&A $4.4M, restructuring costs $2.5M.
- Phase 1b NC410 combo with pembrolizumab data at ASCO June 1, including additional 20 CRC patients.
- LNCB74 (B7-H4 ADC) advancing; IND submission planned by year-end with GLP tox studies initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/0001558370-24-006543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024006543/nxtc-20240502x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer